Cargando…

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis

OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kiyoka, Hasegawa, Shiori, Nakao, Satoshi, Shimada, Kazuyo, Mukai, Ririka, Tanaka, Mizuki, Satake, Riko, Yoshida, Yu, Goto, Fumiya, Inoue, Misaki, Ikesue, Hiroaki, Iguchi, Kazuhiro, Hashida, Tohru, Nakamura, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686594/
https://www.ncbi.nlm.nih.gov/pubmed/33282307
http://dx.doi.org/10.1177/2050312120974176
_version_ 1783613359438954496
author Matsumoto, Kiyoka
Hasegawa, Shiori
Nakao, Satoshi
Shimada, Kazuyo
Mukai, Ririka
Tanaka, Mizuki
Satake, Riko
Yoshida, Yu
Goto, Fumiya
Inoue, Misaki
Ikesue, Hiroaki
Iguchi, Kazuhiro
Hashida, Tohru
Nakamura, Mitsuhiro
author_facet Matsumoto, Kiyoka
Hasegawa, Shiori
Nakao, Satoshi
Shimada, Kazuyo
Mukai, Ririka
Tanaka, Mizuki
Satake, Riko
Yoshida, Yu
Goto, Fumiya
Inoue, Misaki
Ikesue, Hiroaki
Iguchi, Kazuhiro
Hashida, Tohru
Nakamura, Mitsuhiro
author_sort Matsumoto, Kiyoka
collection PubMed
description OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s syndrome using the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. The reporting odds ratio and proportional reporting rate were used to detect the pharmacovigilance signal. RESULTS: The US Food and Drug Administration Adverse Event Reporting System contains 12,201,620 reports from January 2004 to June 2020, of which 186 are on Reye’s syndrome. The Japanese Adverse Drug Event Report contains 646,779 reports from April 2004 to September 2020, of which 30 are on Reye’s syndrome. In the US Food and Drug Administration Adverse Event Reporting System database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, acetaminophen, and valproate sodium were 404.6 (302.6–541.0, n = 80), 15.1 (6.7–34.1, n = 6), 26.2 (16.1–42.6, n = 18), 10.7 (5.5–20.9, n = 9), and 47.1 (26.2–84.6, n = 12), respectively. In the Japanese Adverse Drug Event Report database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, loxoprofen, acetaminophen, and valproate sodium were 14.1 (5.4–36.8, n = 5), 51.7 (22.2–120.5, n = 7), 135.0 (40.8–446.2, n = 3), 17.6 (6.7–46.0, n = 5), 24.0 (9.2–62.6, n = 5), and 13.8 (3.3–57.9, n = 2), respectively. The reported number of female patients aged 30–39 years was the highest in the Japanese Adverse Drug Event Report. CONCLUSION: Although the frequency of the occurrence of Reye’s syndrome is low, the possible risk of the disease occurring in adult females should be considered.
format Online
Article
Text
id pubmed-7686594
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-76865942020-12-03 Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis Matsumoto, Kiyoka Hasegawa, Shiori Nakao, Satoshi Shimada, Kazuyo Mukai, Ririka Tanaka, Mizuki Satake, Riko Yoshida, Yu Goto, Fumiya Inoue, Misaki Ikesue, Hiroaki Iguchi, Kazuhiro Hashida, Tohru Nakamura, Mitsuhiro SAGE Open Med Original Article OBJECTIVES: Reye’s syndrome is a rare and potentially fatal illness that is defined as encephalopathy accompanied by liver failure. The aim of this study was to assess Reye’s syndrome profiles by analyzing data from the spontaneous reporting system database. METHODS: We analyzed reports of Reye’s syndrome using the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. The reporting odds ratio and proportional reporting rate were used to detect the pharmacovigilance signal. RESULTS: The US Food and Drug Administration Adverse Event Reporting System contains 12,201,620 reports from January 2004 to June 2020, of which 186 are on Reye’s syndrome. The Japanese Adverse Drug Event Report contains 646,779 reports from April 2004 to September 2020, of which 30 are on Reye’s syndrome. In the US Food and Drug Administration Adverse Event Reporting System database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, acetaminophen, and valproate sodium were 404.6 (302.6–541.0, n = 80), 15.1 (6.7–34.1, n = 6), 26.2 (16.1–42.6, n = 18), 10.7 (5.5–20.9, n = 9), and 47.1 (26.2–84.6, n = 12), respectively. In the Japanese Adverse Drug Event Report database, the reporting odds ratios (95% confidence interval, number of cases) of aspirin, diclofenac, ibuprofen, loxoprofen, acetaminophen, and valproate sodium were 14.1 (5.4–36.8, n = 5), 51.7 (22.2–120.5, n = 7), 135.0 (40.8–446.2, n = 3), 17.6 (6.7–46.0, n = 5), 24.0 (9.2–62.6, n = 5), and 13.8 (3.3–57.9, n = 2), respectively. The reported number of female patients aged 30–39 years was the highest in the Japanese Adverse Drug Event Report. CONCLUSION: Although the frequency of the occurrence of Reye’s syndrome is low, the possible risk of the disease occurring in adult females should be considered. SAGE Publications 2020-11-20 /pmc/articles/PMC7686594/ /pubmed/33282307 http://dx.doi.org/10.1177/2050312120974176 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Matsumoto, Kiyoka
Hasegawa, Shiori
Nakao, Satoshi
Shimada, Kazuyo
Mukai, Ririka
Tanaka, Mizuki
Satake, Riko
Yoshida, Yu
Goto, Fumiya
Inoue, Misaki
Ikesue, Hiroaki
Iguchi, Kazuhiro
Hashida, Tohru
Nakamura, Mitsuhiro
Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title_full Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title_fullStr Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title_full_unstemmed Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title_short Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
title_sort assessment of reye’s syndrome profile with data from the us food and drug administration adverse event reporting system and the japanese adverse drug event report databases using the disproportionality analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686594/
https://www.ncbi.nlm.nih.gov/pubmed/33282307
http://dx.doi.org/10.1177/2050312120974176
work_keys_str_mv AT matsumotokiyoka assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT hasegawashiori assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT nakaosatoshi assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT shimadakazuyo assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT mukairirika assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT tanakamizuki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT satakeriko assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT yoshidayu assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT gotofumiya assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT inouemisaki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT ikesuehiroaki assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT iguchikazuhiro assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT hashidatohru assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis
AT nakamuramitsuhiro assessmentofreyessyndromeprofilewithdatafromtheusfoodanddrugadministrationadverseeventreportingsystemandthejapaneseadversedrugeventreportdatabasesusingthedisproportionalityanalysis